Inhibrx Biosciences Option Alert: Nov 21 $12.5 Puts at the Ask: 3000 vs 2011 OI; Earnings 11/13 After Close [est] 

Inhibrx Biosciences Option Alert: Nov 21 $12.5 Puts at the Ask: 3000 @ $3.3 vs 2011 OI; Earnings 11/13 After Close [est] Ref=$33.62

Inhibrx Biosciences

INHIBRX BIOSCIENCES INC

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

Earnings

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

AREB

ASNS

DECK

DVLT

INBX

INEO

INTC

MOFG

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SCNX

VIVK

WGRX

YGMZ

Connexa Sports Technologies Inc. - Common Stock

YYAI

El premercado se tiñe de verde con fuertes subidas en tecnología, salud y finanzas tras una oleada de resultados mejores de lo esperado.

Acciones de Intel suben alrededor de un 8%; Aquí están 20 acciones que se mueven en el premercado

Long Ideas

Insider Trades

HNRG

TCBI

Descubre por qué los insiders están comprando acciones en grandes cantidades. ¿Podría señalar una oportunidad de inversión a largo plazo?

Hallador Energy y otras 2 acciones que los insiders están comprando

Inhibrx Biosciences Inc

Inhibrx Inc COM

Press Releases

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Inhibrx Reports First Quarter 2025 Financial Results

Inhibrx Reports Second Quarter 2025 Financial Results

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

ADC Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

enGene Holdings

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

Immuneering Corporation - Class A Common Stock

Immuneering

Invivyd

Jade Biosciences

Kamada

Keros Therapeutics

Korro Bio

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Neurogene

Ocugen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Comments

Inhibrx Biosciences

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL